162 related articles for article (PubMed ID: 30013686)
21. Phage Display-Based Homing Peptide-Daunomycin Conjugates for Selective Drug Targeting to PANC-1 Pancreatic Cancer.
Dókus LE; Lajkó E; Ranđelović I; Mező D; Schlosser G; Kőhidai L; Tóvári J; Mező G
Pharmaceutics; 2020 Jun; 12(6):. PubMed ID: 32580307
[TBL] [Abstract][Full Text] [Related]
22. Simultaneous incorporations of two anticancer drugs into DNA. The structures of formaldehyde-cross-linked adducts of daunorubicin-d(CG(araC)GCG) and doxorubicin-d(CA(araC)GTG) complexes at high resolution.
Zhang H; Gao YG; van der Marel GA; van Boom JH; Wang AH
J Biol Chem; 1993 May; 268(14):10095-101. PubMed ID: 8486678
[TBL] [Abstract][Full Text] [Related]
23. In vitro degradation and antitumor activity of oxime bond-linked daunorubicin-GnRH-III bioconjugates and DNA-binding properties of daunorubicin-amino acid metabolites.
Orbán E; Mezo G; Schlage P; Csík G; Kulić Z; Ansorge P; Fellinger E; Möller HM; Manea M
Amino Acids; 2011 Jul; 41(2):469-83. PubMed ID: 20953647
[TBL] [Abstract][Full Text] [Related]
24. Doxorubicin- and daunorubicin-glutathione conjugates, but not unconjugated drugs, competitively inhibit leukotriene C4 transport mediated by MRP/GS-X pump.
Priebe W; Krawczyk M; Kuo MT; Yamane Y; Savaraj N; Ishikawa T
Biochem Biophys Res Commun; 1998 Jun; 247(3):859-63. PubMed ID: 9647783
[TBL] [Abstract][Full Text] [Related]
25. Differential effect of the calmodulin inhibitor trifluoperazine on cellular accumulation, retention, and cytotoxicity of anthracyclines in doxorubicin (adriamycin)-resistant P388 mouse leukemia cells.
Ganapathi R; Grabowski D; Rouse W; Riegler F
Cancer Res; 1984 Nov; 44(11):5056-61. PubMed ID: 6488165
[TBL] [Abstract][Full Text] [Related]
26. In Vivo Tumor Growth Inhibition and Antiangiogenic Effect of Cyclic NGR Peptide-Daunorubicin Conjugates Developed for Targeted Drug Delivery.
Tripodi AAP; Ranđelović I; Biri-Kovács B; Szeder B; Mező G; Tóvári J
Pathol Oncol Res; 2020 Jul; 26(3):1879-1892. PubMed ID: 31820302
[TBL] [Abstract][Full Text] [Related]
27. Design, synthesis, in vitro stability and cytostatic effect of multifunctional anticancer drug-bioconjugates containing GnRH-III as a targeting moiety.
Leurs U; Mező G; Orbán E; Öhlschläger P; Marquardt A; Manea M
Biopolymers; 2012; 98(1):1-10. PubMed ID: 21509746
[TBL] [Abstract][Full Text] [Related]
28. Double targeting, controlled release and reversible delivery of daunorubicin to cancer cells by polyvalent aptamers-modified gold nanoparticles.
Taghdisi SM; Danesh NM; Lavaee P; Emrani AS; Hassanabad KY; Ramezani M; Abnous K
Mater Sci Eng C Mater Biol Appl; 2016 Apr; 61():753-61. PubMed ID: 26838906
[TBL] [Abstract][Full Text] [Related]
29. Synthesis, enzymatic stability and in vitro cytostatic effect of Daunorubicin-GnRH-III derivative dimers.
Schreier VN; Mező G; Orbán E; Dürr C; Marquardt A; Manea M
Bioorg Med Chem Lett; 2013 Apr; 23(7):2145-50. PubMed ID: 23434423
[TBL] [Abstract][Full Text] [Related]
30. PEG-doxorubicin conjugates: influence of polymer structure on drug release, in vitro cytotoxicity, biodistribution, and antitumor activity.
Veronese FM; Schiavon O; Pasut G; Mendichi R; Andersson L; Tsirk A; Ford J; Wu G; Kneller S; Davies J; Duncan R
Bioconjug Chem; 2005; 16(4):775-84. PubMed ID: 16029018
[TBL] [Abstract][Full Text] [Related]
31. Poly(ethylene glycol)-poly(ester-carbonate) block copolymers carrying PEG-peptidyl-doxorubicin pendant side chains: synthesis and evaluation as anticancer conjugates.
Andersson L; Davies J; Duncan R; Ferruti P; Ford J; Kneller S; Mendichi R; Pasut G; Schiavon O; Summerford C; Tirk A; Veronese FM; Vincenzi V; Wu G
Biomacromolecules; 2005; 6(2):914-26. PubMed ID: 15762660
[TBL] [Abstract][Full Text] [Related]
32. Are cardioprotective effects of NO-releasing drug molsidomine translatable to chronic anthracycline cardiotoxicity settings?
Lenčová-Popelová O; Jansová H; Jirkovský E; Bureš J; Jirkovská-Vávrová A; Mazurová Y; Reimerová P; Vostatková L; Adamcová M; Hroch M; Pokorná Z; Kovaříková P; Šimůnek T; Štěrba M
Toxicology; 2016 Nov; 372():52-63. PubMed ID: 27816693
[TBL] [Abstract][Full Text] [Related]
33. Comparison of mechanisms responsible for resistance to idarubicin and daunorubicin in multidrug resistant LoVo cell lines.
Toffoli G; Simone F; Gigante M; Boiocchi M
Biochem Pharmacol; 1994 Nov; 48(10):1871-81. PubMed ID: 7986198
[TBL] [Abstract][Full Text] [Related]
34. New daunomycin-oligoarginine conjugates: synthesis, characterization, and effect on human leukemia and human hepatoma cells.
Miklán Z; Orbán E; Csík G; Schlosser G; Magyar A; Hudecz F
Biopolymers; 2009; 92(6):489-501. PubMed ID: 19521976
[TBL] [Abstract][Full Text] [Related]
35. Cardioprotective effects of inorganic nitrate/nitrite in chronic anthracycline cardiotoxicity: Comparison with dexrazoxane.
Lenčová-Popelová O; Jirkovský E; Jansová H; Jirkovská-Vávrová A; Vostatková-Tichotová L; Mazurová Y; Adamcová M; Chládek J; Hroch M; Pokorná Z; Geršl V; Šimůnek T; Štěrba M
J Mol Cell Cardiol; 2016 Feb; 91():92-103. PubMed ID: 26724189
[TBL] [Abstract][Full Text] [Related]
36. Targeted and controlled release delivery of daunorubicin to T-cell acute lymphoblastic leukemia by aptamer-modified gold nanoparticles.
Danesh NM; Lavaee P; Ramezani M; Abnous K; Taghdisi SM
Int J Pharm; 2015 Jul; 489(1-2):311-7. PubMed ID: 25936625
[TBL] [Abstract][Full Text] [Related]
37. Effect of doxorubicin on lipid peroxide levels in tissues of mice.
Sazuka Y; Yoshikawa K; Tanizawa H; Takino Y
Jpn J Cancer Res; 1987 Nov; 78(11):1281-6. PubMed ID: 3121563
[TBL] [Abstract][Full Text] [Related]
38. Development of novel cyclic NGR peptide-daunomycin conjugates with dual targeting property.
Tripodi AAP; Tóth S; Enyedi KN; Schlosser G; Szakács G; Mező G
Beilstein J Org Chem; 2018; 14():911-918. PubMed ID: 29765472
[TBL] [Abstract][Full Text] [Related]
39. Characterization and modulation of drug transport kinetics in K562 c1.6 daunorubicin-resistant cell line.
Jiang XR; Macey MG; Collins PW; Newland AC
Br J Haematol; 1994 Mar; 86(3):547-54. PubMed ID: 8043436
[TBL] [Abstract][Full Text] [Related]
40. Among substituted 9,10-dihydro-9,10-[1,2]benzenoanthracene-1,4,5,8-tetraones, the lead antitumor triptycene bisquinone TT24 blocks nucleoside transport, induces apoptotic DNA fragmentation and decreases the viability of L1210 leukemic cells in the nanomolar range of daunorubicin in vitro.
Perchellet EM; Sperfslage BJ; Wang Y; Huang X; Tamura M; Hua DH; Perchellet JP
Anticancer Drugs; 2002 Jul; 13(6):567-81. PubMed ID: 12172502
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
